Food, Drugs, Healthcare, Life Sciences

Following widespread litigation over Halozyme's SPC families for Herceptin Hylecta and MabThera, Europe's highest court received a critical referral addressing whether recombinant human hyaluronidase can be considered an "active ingredient" despite its classification as an excipient in marketing authorisation documents. Advocate General Emiliou has now published a significant legal opinion proposing that substances expressly designated as excipients cannot be regarded as active ingredients for SPC purposes.

Bär & Karrer, a Swiss law firm, provides comprehensive legal and business solutions. Contact their Zurich office for expert assistance with legal advice, business inquiries, and professional services tailored to your needs.

The cinematic release of the 2021 novel, Project Hail Mary, has received rave reviews, with audiences praising the film as a faithful and visually stunning adaptation of the book.

Half of women working in law say the demands of their job are unsustainable for their long-term health, according to new research which canvassed the views of more than 500 female legal professionals.

Medical malpractice encompasses preventable healthcare errors that cause serious harm to patients. Understanding common examples—from misdiagnosis and surgical mistakes to medication...

Recent investigations reveal the systemic pressures facing UK maternity care, raising critical questions about safety standards, accountability and the legal framework supporting families when care falls short. What does the evidence tell us about the current state of maternity services, and how can legal processes drive meaningful improvement?

For developers, seed companies, and their advisers, this development provides long-awaited certainty on regulatory pathways for gene edited crops.

The clinical success of PARP inhibitors has validated DNA damage response (DDR) as a major therapeutic target in oncology, but resistance to first-generation therapies is driving innovation toward new strategies.

The European Parliament has approved new regulations for gene-edited crops, establishing a two-tier framework that distinguishes between plants equivalent to conventional breeding and those requiring full GMO oversight. The legislation preserves patent protection while introducing transparency measures and public databases to track NGT-derived varieties across the European Union.